The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Subscribe To Our Newsletter & Stay Updated
